



MEDICAL PRODUCT ALERT

DRAP ALERT NO. N° I/S/2-25-

SUBSTANDARD PRODUCTS DECLARED BY PROVINCIAL DRUG TESTING LABORATORIES.

Date: 20th February, 2025

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses).
- General Public.

Alert Summary:

Directorate of Drug Control (DDC) Punjab has informed Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been reported as '*Substandard*'.

S#	Product Name	Batch No.	Manufacturers	Remarks
1.	Infusion Safemed 100mL (Metronidazole 500mg /100ml) Reg. No. 045824	S-790-A	M/s. Ahad International Pharmaceuticals Ltd. 13-Km, Gomal University, Multan Road, Dera Ismail Khan.	'Substandard' on the basis of Visible Particulates and Extractable volume.
2.	Syrup Resfyl 60mL Each 5 mL contains: Acefylline Piperazine 45mg Diphenhydramine HCl 8mg Reg. No. 057214	4A009	M/s. Rasco Pharma, 5.5-Km, Raiwind Road, Lahore.	'Substandard' on the basis of presence of Impurity (Ethylene glycol) above the permissible limit.
3.	Sterile Water for Injection Reg. No. 024854	224	M/s. Pharmedic Labs (Pvt) Ltd, 16-Km Multan Road, Lahore.	'Substandard' on the basis of Visible Particulates.
4.	Injection Ame-Pin Tramdol HCl 100mg/2mL Reg. No. 065943	TD-038	M/s. Ameer Pharma (Pvt) Ltd, 23-Km, Sheikhpura Road, Lahore.	'Substandard' on the basis of Visible Particulates.



DRAP, Islamabad



+92 051 9255969



gsms@dra.gov.pk



Risk Statement:

The use of substandard products can result in therapy failure, increasing the risk of complications, particularly in vulnerable groups such as immunocompromised individuals, as well as pediatric and geriatric population.

Action initiated: -

The field force under administrative control of DRAP and Provincial Drug Control departments have been directed to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.

Advice for Pharmacies/Medical stores: -

All pharmacists and chemist working at distributions and pharmacies should **immediately check** their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) should also increase surveillance in the market to ensure the effective recall of defective products(s).

Advice for Healthcare Professionals: -

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above mentioned product are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this [link](#). Further information of reporting problems to DRAP is available on this [link](#).

Advice for Consumers/general public: -

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.



Drug Regulatory Authority of Pakistan

محفوظ، موثر اور معیاری اشیائے علاج



DRAP, Islamabad



+92 051 9255969



gsms@dra.gov.pk